{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:26:11Z","timestamp":1769732771058,"version":"3.49.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T00:00:00Z","timestamp":1635811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pfizer Inc"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,11,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>This study aimed to evaluate the risk factor and incidence of infections in patients receiving tumor necrosis factor inhibitor (TNFi) therapy for ankylosing spondylitis using data from the national health insurance service.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a retrospective cohort study. Data regarding patients with ankylosing spondylitis prescribed TNFis were obtained from an insurance claims database of the Health Insurance Review &amp; Assessment Service in Korea. Outcomes used were incidence rates of serious infection, pneumonia, tuberculosis, and herpes zoster during the follow-up period as well as the relationship between each TNFi and sex, hazard ratio (HR) of infection-related risk factors, and incidence of infections.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 2515 patients were included. There were no significant differences among the hazard ratios of TNFis for serious infection, pneumonia, and herpes zoster. However, the hazard ratio of tuberculosis was significantly higher for infliximab than for etanercept (adjusted HR 8.40 [95% confidence interval: 1.06\u201366.91]). In the subgroup analysis by sex, women treated with golimumab had a significantly higher hazard of herpes zoster than those treated with etanercept (adjusted HR 12.40 [95% confidence interval: 1.40\u2013109.58]).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>We recommend that risk factors for these infectious diseases be identified prior to prescribing TNFis in these patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1080\/14397595.2021.1878985","type":"journal-article","created":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T08:51:35Z","timestamp":1611651095000},"page":"1192-1201","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":13,"title":["The risk factors and incidence of major infectious diseases in patients with ankylosing spondylitis receiving tumor necrosis factor inhibitors"],"prefix":"10.1093","volume":"31","author":[{"given":"Bon San","family":"Koo","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Inje University Seoul Paik Hospital, Inje University College of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Cheol","family":"Lim","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Young","family":"Lee","sequence":"additional","affiliation":[{"name":"VIAplus, Suwon, Gyeonggi-do, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ja-Young","family":"Jeon","sequence":"additional","affiliation":[{"name":"Pfizer Inc., Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun-Jeong","family":"Yoo","sequence":"additional","affiliation":[{"name":"Pfizer Inc., Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In-Sun","family":"Oh","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju-Young","family":"Shin","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae-Hwan","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,11,2]]},"reference":[{"issue":"9","key":"2021101808424680100_CIT0001","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nri1184","article-title":"Signalling pathways of the TNF superfamily: a double-edged sword","volume":"3","author":"Aggarwal","year":"2003","journal-title":"Nat Rev Immunol"},{"issue":"2-3","key":"2021101808424680100_CIT0002","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1385\/IR:27:2-3:529","article-title":"Regulation of inflammation","volume":"27","author":"Sullivan","year":"2003","journal-title":"IR"},{"issue":"1","key":"2021101808424680100_CIT0003","doi-asserted-by":"crossref","first-page":"e000396","DOI":"10.1136\/rmdopen-2016-000396","article-title":"Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS\/EULAR recommendations for the management of axial spondyloarthritis","volume":"3","author":"Sepriano","year":"2017","journal-title":"RMD Open"},{"issue":"6","key":"2021101808424680100_CIT0004","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"2021101808424680100_CIT0005","doi-asserted-by":"crossref","first-page":"718","DOI":"10.3346\/jkms.2017.32.5.718","article-title":"Towards Actualizing the Value Potential of Korea Health Insurance Review and Assessment (HIRA) data as a resource for health research: strengths, limitations, applications, and strategies for optimal use of HIRA data","volume":"32","author":"Kim","year":"2017","journal-title":"J Korean Med Sci"},{"key":"2021101808424680100_CIT0006","doi-asserted-by":"crossref","first-page":"e2014008","DOI":"10.4178\/epih\/e2014008","article-title":"A guide for the utilization of health insurance review and assessment service national patient samples","volume":"36","author":"Kim","year":"2014","journal-title":"Epidemiol Health"},{"issue":"5","key":"2021101808424680100_CIT0007","doi-asserted-by":"crossref","first-page":"e0124287","DOI":"10.1371\/journal.pone.0124287","article-title":"Differential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort study","volume":"10","author":"Seong","year":"2015","journal-title":"PLOS One"},{"key":"2021101808424680100_CIT0008","doi-asserted-by":"crossref","first-page":"h3517","DOI":"10.1136\/bmj.h3517","article-title":"Risk of intracranial haemorrhage in antidepressant users with concurrent use of non-steroidal anti-inflammatory drugs: nationwide propensity score matched study","volume":"351","author":"Shin","year":"2015","journal-title":"BMJ"},{"issue":"4","key":"2021101808424680100_CIT0009","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.semarthrit.2017.08.007","article-title":"Persistence of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: an analysis of the South Korean National Health Insurance Database","volume":"47","author":"Lee","year":"2018","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"2021101808424680100_CIT0010","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s12325-012-0037-5","article-title":"Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings","volume":"29","author":"Bonafede","year":"2012","journal-title":"Adv Ther"},{"issue":"1","key":"2021101808424680100_CIT0011","doi-asserted-by":"crossref","first-page":"6736","DOI":"10.1038\/s41598-019-43155-0","article-title":"Impact of ankylosing spondylitis on depression: a nationwide cohort study","volume":"9","author":"Park","year":"2019","journal-title":"Sci Rep"},{"issue":"11","key":"2021101808424680100_CIT0012","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1177\/1352458516681198","article-title":"Infection-related health care utilization among people with and without multiple sclerosis","volume":"23","author":"Wijnands","year":"2017","journal-title":"Mult Scler"},{"issue":"5","key":"2021101808424680100_CIT0013","doi-asserted-by":"crossref","first-page":"727","DOI":"10.3201\/eid1405.071011","article-title":"Increasing hospital admissions for pneumonia, England","volume":"14","author":"Trotter","year":"2008","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"2021101808424680100_CIT0014","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1136\/thx.2006.059451","article-title":"Coeliac disease and risk of tuberculosis: a population based cohort study","volume":"62","author":"Ludvigsson","year":"2007","journal-title":"Thorax"},{"issue":"2","key":"2021101808424680100_CIT0015","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jinf.2014.08.018","article-title":"Incidence of herpes zoster and its complications in Germany, 2005\u20132009","volume":"70","author":"Hillebrand","year":"2015","journal-title":"J Infect"},{"issue":"10","key":"2021101808424680100_CIT0016","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1136\/ard.2008.098822","article-title":"Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebo-controlled trials","volume":"69","author":"Fouque-Aubert","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2021101808424680100_CIT0017","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/rheumatology\/keu255","article-title":"Tumour necrosis factor inhibitor therapy and infection risk in axial spondyloarthritis: results from a longitudinal observational cohort","volume":"54","author":"Wallis","year":"2015","journal-title":"Rheumatology"},{"key":"2021101808424680100_CIT0018","doi-asserted-by":"crossref","DOI":"10.1080\/03009742.2018.1470253","article-title":"Use of disease-modifying anti-rheumatic or anti-tumour necrosis factor drugs and risk of hospitalized infection in ankylosing spondylitis","author":"Moura","year":"2019","journal-title":"Scand J Rheumatol"},{"issue":"6","key":"2021101808424680100_CIT0019","doi-asserted-by":"crossref","first-page":"e0178035","DOI":"10.1371\/journal.pone.0178035","article-title":"The risk of tuberculosis disease in rheumatoid arthritis patients on biologics and targeted therapy: a 15-year real world experience in Taiwan","volume":"12","author":"Lim","year":"2017","journal-title":"PLOS One"},{"key":"2021101808424680100_CIT0020","article-title":"The other side of the coin: anti-inflammatory antibody therapy for infectious diseases","volume":"88","author":"Goldman","year":"2019","journal-title":"Infect Immun"},{"issue":"3","key":"2021101808424680100_CIT0021","doi-asserted-by":"crossref","first-page":"e0194598","DOI":"10.1371\/journal.pone.0194598","article-title":"Incidence and case fatality rates of community-acquired pneumonia and pneumococcal diseases among Korean adults: catchment population-based analysis","volume":"13","author":"Heo","year":"2018","journal-title":"PLOS One"},{"issue":"1","key":"2021101808424680100_CIT0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"2021101808424680100_CIT0023","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/1756-185X.12530","article-title":"Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden","volume":"18","author":"Jung","year":"2015","journal-title":"Int J Rheum Dis"},{"issue":"3","key":"2021101808424680100_CIT0024","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/1756-185X.12515","article-title":"Evaluation of the usefulness of interferon-gamma release assays and the tuberculin skin test for the detection of latent Mycobacterium tuberculosis infections in Korean rheumatic patients who are candidates for biologic agents","volume":"18","author":"Kim","year":"2015","journal-title":"Int J Rheum Dis"},{"issue":"10","key":"2021101808424680100_CIT0025","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.3899\/jrheum.110373","article-title":"Incidence of tuberculosis among Korean patients with ankylosing spondylitis who are taking tumor necrosis factor blockers","volume":"38","author":"Kim","year":"2011","journal-title":"J Rheumatol"},{"issue":"10","key":"2021101808424680100_CIT0026","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1473-3099(08)70227-5","article-title":"Tumour necrosis factor antagonists: structure, function, and tuberculosis risks","volume":"8","author":"Wallis","year":"2008","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"2021101808424680100_CIT0027","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1080\/14397595.2017.1325034","article-title":"The risk of herpes zoster in patients with ankylosing spondylitis: Analysis of the Korean National Health Insurance Service \u2013 sample cohort database","volume":"28","author":"Lim","year":"2018","journal-title":"Mod Rheumatol"},{"issue":"8","key":"2021101808424680100_CIT0028","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/rheumatology\/keu014","article-title":"The presence of peripheral arthritis delays spinal radiographic progression in ankylosing spondylitis: Observation Study of the Korean Spondyloarthropathy Registry","volume":"53","author":"Kim","year":"2014","journal-title":"Rheumatology"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/mr\/article-pdf\/31\/6\/1192\/40675825\/mr1192.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/mr\/article-pdf\/31\/6\/1192\/40675825\/mr1192.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T02:55:56Z","timestamp":1642560956000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/31\/6\/1192-1201\/6398463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,2]]},"references-count":28,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,11,2]]},"published-print":{"date-parts":[[2021,11,2]]}},"URL":"https:\/\/doi.org\/10.1080\/14397595.2021.1878985","relation":{},"ISSN":["1439-7609","1439-7595"],"issn-type":[{"value":"1439-7609","type":"electronic"},{"value":"1439-7595","type":"print"}],"subject":[],"published-other":{"date-parts":[[2021,11,2]]},"published":{"date-parts":[[2021,11,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=imor20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=imor20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-09-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}